Core Insights - The biochemical diagnosis industry in China is projected to reach a market size of 29.2 billion yuan in 2024, reflecting a year-on-year growth of 5.80% driven by increasing medical demand and advancements in diagnostic technology [2][8]. Industry Overview - Biochemical diagnosis, also known as clinical biochemical testing, is a crucial branch of in vitro diagnostics (IVD) that utilizes biochemical methods to measure specific biochemical indicators in body fluids for disease diagnosis, treatment monitoring, and health assessment [3][4]. Industry Chain - The upstream of the biochemical diagnosis industry includes biological raw materials such as enzyme preparations, antigens, antibodies, and chemical raw materials like sodium chloride and amino acids. The midstream focuses on the research and production of diagnostic reagents and instruments, while the downstream applications are found in hospitals, clinics, independent medical laboratories, health examination centers, and blood stations [6]. Market Demand Drivers - The aging population and increasing health awareness are driving the demand for medical services, with the number of hospitals in China expected to reach 38,700 in 2024, a 0.90% increase year-on-year. This growth in hospital numbers is expected to boost the demand for biochemical diagnostic products and services [8]. Technological Advancements - Recent advancements in biochemical diagnostic technology, including new enzyme detection methods and high-throughput detection platforms, have improved testing efficiency and accuracy while reducing costs, further stimulating market demand [2][8]. Relevant Policies - The Chinese government has introduced various policies to promote the healthy development of the biochemical diagnosis industry, including the "Measurement Support for New Quality Productivity Development Action Plan (2025-2030)" aimed at enhancing measurement and quality evaluation technologies in key health sectors [9][12].

Group 1 - China Ping An completed stock purchase under the 2025 long-term service plan, acquiring 74.615 million H-shares, accounting for 0.412% of total share capital, with a total transaction amount of 3.875 billion yuan [1] - New China Life Insurance reported original insurance premium income of 158.086 billion yuan from January to August, representing a year-on-year increase of 21% [7] - Longhua Group received a project development notification from a domestic automaker, with an estimated total sales amount of approximately 280 million yuan over a 5-year project lifecycle [8] Group 2 - Tianlong Co., Ltd. announced that its general manager plans to reduce holdings by up to 320,000 shares, representing 0.16% of total share capital, due to personal financial needs [2] - Pingzhi Information became a candidate for a 170 million yuan AI computing power technology service project [3] - Shandong Mining announced the establishment of a holding subsidiary with a registered capital of 10 million yuan, in which it holds a 65% stake [4] Group 3 - Haixia Environmental Protection plans to invest 60.6059 million yuan in upgrading a sewage treatment project [5] - Zaiqi Pharmaceutical received approval for clinical trials of its injection drug ZGGS34 for treating MUC17 positive advanced solid tumors [6] - Hengrui Medicine's application for a new indication for SHR-A1811 for HER2 positive breast cancer was accepted and included in the priority review process [16][17] Group 4 - Vanke A received a loan support of 2.064 billion yuan from its largest shareholder, Shenzhen Metro Group, for debt repayment [38] - Guang'an Aizhong plans to acquire 90% of Qitai Hengzong at a price of 0 yuan to expand its wind power business [39] - A total of 6 products from Jiuzhang Bio received IVDR CE certification, valid until September 10, 2030 [20]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月17日，九强生物发布公告称，公司6项产品于近日获得 欧盟IVDR CE认证。6项产品分别是D—二聚体测定试剂盒(胶乳免疫比浊法)、钾测定试剂盒(丙酮酸激 酶法)、钠测定试剂盒(半乳糖苷酶法)、总胆汁酸测定试剂盒（循环酶法）、高密度脂蛋白胆固醇测定试 剂盒（直接法—过氧化物酶清除法）、低密度脂蛋白胆固醇测定试剂盒（直接法—表面活性剂清除 法）。 ...

格隆汇9月17日丨九强生物(300406.SZ)公布，公司6项产品于近日获得欧盟IVDRCE认证，本次IVDR CE证书的获得，表明公司相关产品符 合欧盟要求，具备进入欧盟市场的必要条件，有利于满足国际市场客户多样化的临床需求，进一步增强公司产品的综合竞争力。 | 序号 | 产品名称 | 有效期 | 证书编号 | 预期用途 | | --- | --- | --- | --- | --- | | 1 | D-二聚体测定试剂盒(胶 | 2030-09-10 | HX 2165478-1 | 用于体外定量测定人血 | | | 乳免疫比浊法) | | | 浆中D-二聚体的含量。 | | 2 | 钾测定试剂盒(丙酮酸激 | 2030-09-10 | HX 2165478-1 | 用于体外定量测定人血 | | | 酶法) | | | 清或血浆中钾的含量。 | | 3 | 钠测定试剂盒(半乳糖苷 | 2030-09-10 | HX 2165478-1 | 用于体外定量测定人血 | | | 酶法) | | | 清或血浆中钠的含量。 | | 4 | 总胆汁酸测定试剂盒(循 | 2030-09-10 | HX 2165478-1 ...

智通财经APP讯，九强生物(300406.SZ)公告，公司6项产品于近日获得欧盟IVDR CE认证，包括：D-二 聚体测定试剂盒(胶乳免疫比浊法)、钾测定试剂盒(丙酮酸激酶法)、钠测定试剂盒(半乳糖苷酶法)、总胆 汁酸测定试剂盒(循环酶法)、高密度脂蛋白胆固醇测定试剂盒(直接法—过氧化物酶清除法)、低密度脂 蛋白胆固醇测定试剂盒(直接法—表面活性剂清除法)。 ...

九强生物（300406）(300406.SZ)公告，公司6项产品于近日获得欧盟IVDR CE认证，包括：D-二聚体测 定试剂盒(胶乳免疫比浊法)、钾测定试剂盒(丙酮酸激酶法)、钠测定试剂盒(半乳糖苷酶法)、总胆汁酸测 定试剂盒(循环酶法)、高密度脂蛋白胆固醇测定试剂盒(直接法—过氧化物酶清除法)、低密度脂蛋白胆 固醇测定试剂盒(直接法—表面活性剂清除法)。 ...

Core Viewpoint - The company Jiukang Bio (300406.SZ) has recently obtained EU IVDR CE certification for six of its products, indicating compliance with EU standards and readiness for entry into the EU market [1] Product Certification - The six products that received certification include: - D-Dimer assay kit - Potassium assay kit - Sodium assay kit - Total bile acid assay kit - High-density lipoprotein cholesterol assay kit - Low-density lipoprotein cholesterol assay kit [1] Market Implications - The certification enhances the company's ability to meet diverse clinical needs in the international market, thereby strengthening the overall competitiveness of its products [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、 误导性陈述或重大遗漏。 北京九强生物技术股份有限公司(以下简称"公司") 6 项产品于近日获得 欧盟 IVDR CE 认证，具体情况如下： | 序号 | 产品名称 | 有效期 | | 证书编号 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | D-二聚体测定试剂盒(胶 乳免疫比浊法) | 2030-09-10 | HX | 2165478-1 | 用于体外定量测定人血 浆中D-二聚体的含量。 | | 2 | 钾测定试剂盒(丙酮酸激 酶法) | 2030-09-10 | HX | 2165478-1 | 用于体外定量测定人血 清或血浆中钾的含量。 | | 3 | 钠测定试剂盒(半乳糖苷 酶法) | 2030-09-10 | ...

Group 1 - The Ministry of Commerce and eight other departments released measures to expand service consumption, proposing 19 initiatives to enhance service supply and meet diverse consumer needs [1] - Beijing Minna Star Technology Co., Ltd., a leading satellite manufacturer, has initiated an IPO with a valuation exceeding 7 billion yuan and has secured over 2 billion yuan in funding [1] - The top 10 global semiconductor equipment manufacturers reported a combined revenue of over 64 billion USD in the first half of 2025, marking a year-on-year growth of approximately 24% [1] Group 2 - OpenAI is accelerating its investment in robotics, focusing on humanoid robots as a key step towards achieving artificial general intelligence (AGI) [2] - The real estate market is facing scrutiny over developers' practices of inflating usable area percentages, with new regulations being introduced to standardize building area calculations [2] - A well-known restaurant brand, Taier Sauerkraut Fish, faced criticism regarding its "fresh fish cooked on-site" claims, leading to customer inquiries about its operational practices [3] Group 3 - The vice president of Douyin Group highlighted the emergence of a "ByteDance departure track" on social media, revealing that many posts claiming to be from former employees are misleading and often linked to training institutions [4] - Zhongya Machinery Co., Ltd. has authorized up to 400 million yuan for entrusted wealth management, recently purchasing a 5 million yuan financial product from China Merchants Bank [4] - Su Junliang has been appointed as the chairman of Industrial Securities, succeeding Yang Huahui [5] Group 4 - Jiuxiang Bio has received a medical device registration certificate for its gastrin-17 testing kit, which is used for quantitative measurement of gastrin-17 levels in human serum [6] - Luxiao Technology's subsidiary has signed a strategic cooperation agreement with a leading cross-border e-commerce company to develop AI technology and expand into the US and European markets [7] - China Shipbuilding Technology has signed a significant contract for green methanol sales, with an annual contract value of approximately 40 million USD [8] Group 5 - Haon Automotive has received product designation from a global automotive brand for its ADAS perception system and radar system, with an estimated total revenue of about 2.477 billion yuan over the project's lifecycle [9] - Yaoshi Technology announced that the last day for converting its bonds will be September 17, after which unconverted bonds will be forcibly redeemed at a price of 100.62 yuan per bond [10] - Hefei Urban Construction's subsidiary has signed a land use rights transfer contract for residential land in Hefei, with a total payment of approximately 1.224 billion yuan [11] Group 6 - China Shenhua reported a coal sales volume of 280 million tons in the first eight months of the year, reflecting a year-on-year decline of 9.2% [12] - The ChiNext index experienced a rebound, closing up 0.68%, with the robotics sector leading the market with over 20 stocks hitting the daily limit [13]

Group 1 - China Shenhua reported coal sales of 37.5 million tons in August, a year-on-year decrease of 3.1%, with total sales for the first eight months at 280 million tons, down 9.2% year-on-year [1] - China Shenhua, established in November 2004, focuses on coal and electricity production and sales, as well as transportation and coal-to-olefins [1] - Huaren Shuanghe's subsidiary received a drug registration certificate for a new injection used in treating non-ST elevation acute coronary syndrome [1] - Huaren Shuanghe, founded in May 1997, operates in chronic disease management, specialty business, and infusion business [1] Group 2 - New Wufeng's subsidiary signed a property transaction contract for a 60% equity transfer at a price of 9.7 million yuan [1] - New Wufeng, established in June 2001, specializes in pig farming, meat sales, and feed processing [2] - Yaoshi Technology announced that its convertible bonds will stop conversion after September 17, with remaining bonds to be redeemed at 100.62 yuan per bond [3] - Yaoshi Technology, founded in December 2006, focuses on drug molecular building blocks and related services [3] Group 3 - Newhua Co. announced a board member's plan to reduce holdings by up to 75,200 shares, representing 0.039% of total shares [4] - Newhua Co., established in September 1997, specializes in fine chemical products [4] - Hefei Construction's subsidiary signed a land use rights transfer contract for residential land with a total price of 12.24 billion yuan [6] - Hefei Construction, founded in September 1999, is involved in real estate development and property management [6] Group 4 - Guoyao Modern's subsidiary received a drug registration certificate for an injection used in anesthesia and emergency treatment [7] - Guoyao Modern, established in November 1996, focuses on pharmaceutical product development and sales [7] - Maohua Shihua announced the resignation of its deputy general manager [8] - Maohua Shihua, founded in October 1988, specializes in petrochemical products [9] Group 5 - Zhejiang Xineng applied for enforcement of a civil mediation agreement, seeking 170 million yuan from a group for breach of contract [10] - Zhejiang Xineng, established in December 1991, focuses on renewable energy projects [10] - Zejing Pharmaceutical announced the initiation of key clinical trials for a new drug targeting DLL3 [11] - Zejing Pharmaceutical, founded in March 2009, specializes in the development and production of new chemical and biological drugs [12] Group 6 - Huayi Technology's deputy general manager resigned due to personal work arrangements [13] - Huayi Technology, established in December 1998, focuses on high polymer materials and equipment manufacturing [13] - Luxiao Technology's subsidiary signed a strategic cooperation agreement with a leading cross-border e-commerce company [14] - Luxiao Technology, founded in May 1989, operates in various sectors including photovoltaic power generation [14] Group 7 - Aoxiang Pharmaceutical's subsidiary received a drug registration certificate for a new cancer treatment [15] - Aoxiang Pharmaceutical, established in April 2010, focuses on the development and production of pharmaceutical products [15] - Baiyunshan's pharmaceutical factory received approval for five drug supplement applications [16] - Baiyunshan, founded in September 1997, specializes in the research and production of various pharmaceutical products [16] Group 8 - Renfu Pharmaceutical's subsidiaries received drug registration certificates for two new products [17] - Renfu Pharmaceutical, established in March 1993, focuses on drug research and production [18] - China Shipbuilding Technology signed a significant contract for green methanol sales, potentially worth up to 1.2 billion dollars [19] - China Shipbuilding Technology, founded in May 1997, specializes in wind and solar resource development [19] Group 9 - Haohua Technology received a project designation from a global automotive brand for its ADAS system [20] - Haohua Technology, established in January 2010, focuses on intelligent driving perception systems [20] - Hendi Pharmaceutical received approval for a new raw material drug [21] - Hendi Pharmaceutical, founded in December 1995, specializes in chemical raw materials and formulations [22] Group 10 - JX Communication's subsidiary received a temporary use permit for an air traffic communication system [23] - JX Communication, established in January 1995, focuses on communication technology applications [23] - Longyuan Technology's deputy general manager resigned due to work reasons [24] - Longyuan Technology, founded in December 1998, specializes in energy-saving and environmental protection [25] Group 11 - Jiuqiang Bio received a medical device registration for a gastrin-17 assay kit [26] - Jiuqiang Bio, established in January 2001, focuses on in vitro diagnostic testing platforms [26] - Rifei Co. received approval for a stock issuance to specific investors [27] - Rifei Co., founded in December 2009, specializes in special equipment cables and other electrical devices [27] Group 12 - Huayi Media received a subsidy for a micro-short drama project [28] - Huayi Media, established in August 1998, focuses on film and game content investment [28] - Huilong Pharmaceutical's subsidiary received overseas marketing approvals for multiple products [29] - Huilong Pharmaceutical, founded in October 2010, specializes in innovative and high-quality generic drugs [29] Group 13 - Junsheng Electronics' subsidiary received project designations from two major automotive brands [30] - Junsheng Electronics, established in August 1992, focuses on automotive parts [30] - Silek signed an investment cooperation agreement for a new energy project [31] - Silek, founded in January 2004, specializes in metal packaging equipment [31] Group 14 - ST Huhuwa received drug registration certificates for two new products [32] - ST Huhuwa, established in June 2005, focuses on drug research and production [32] - Canray Technology announced a share buyback plan of 20 to 40 million yuan [33] - Canray Technology, founded in September 2005, specializes in integrated circuits [33] Group 15 - Qilu Bank's directors plan to collectively increase their holdings by at least 3.5 million yuan [34] - Qilu Bank, established in June 1996, focuses on corporate and personal banking services [34] - China Overseas Land reported a significant decrease in contract sales in August [35] - China Overseas Land, founded in September 1997, specializes in tourism and real estate [35] Group 16 - Longjian Co. plans to acquire 100% of Guangdong Zhimao's equity for 40,000 yuan [36] - Longjian Co., established in January 1993, focuses on infrastructure construction [36] - Lichong Group's subsidiary received project designations from a luxury car brand [37] - Lichong Group, founded in July 1998, specializes in aluminum alloy products [37] Group 17 - Kanglong Huacheng's subsidiary passed an FDA inspection [38] - Kanglong Huacheng, established in July 2004, focuses on integrated drug research and development services [38] - Kangtai Bio received a drug registration certificate for a new polio vaccine [39] - Kangtai Bio, founded in September 1992, specializes in vaccine development and production [39] Group 18 - Baiyunshan's pharmaceutical factory's drug entered a key clinical trial phase [40] - Baiyunshan, established in September 1997, focuses on various pharmaceutical products [40] - Zhongyuan Home's chairman plans to reduce holdings by up to 3% [41] - Zhongyuan Home, founded in November 2001, specializes in furniture production [41] Group 19 - Shangluo Electronics plans to acquire 88.79% of Ligon Technology's equity for 709 million yuan [42] - Shangluo Electronics, established in August 1999, focuses on electronic components [42] - Shangluo Electronics also plans to issue convertible bonds to raise 1 billion yuan [43] - Shangluo Electronics, founded in August 1999, specializes in electronic products for various applications [43] Group 20 - HNA Holdings reported a 3.38% increase in passenger capacity in August [44] - HNA Holdings, established in December 1995, focuses on air transportation services [44] - Yipin Hong's subsidiary received a drug registration certificate for a new product [45] - Yipin Hong, founded in February 2002, specializes in pharmaceutical production [45] Group 21 - Haishi Ke's innovative drug received approval for a new indication [46] - Haishi Ke, established in August 2005, focuses on new drug development [46] - Huaxia Airlines plans to repurchase shares worth 80 to 160 million yuan [47] - Huaxia Airlines, founded in April 2006, specializes in air transportation services [47] Group 22 - Jingchen Co. plans to acquire 100% of Xinchip Microelectronics for 316 million yuan [48] - Jingchen Co., established in July 2003, focuses on semiconductor design [48] - Zhongxin Heavy Industry was recognized as an excellent smart factory by the Ministry of Industry and Information Technology [49] - Zhongxin Heavy Industry, founded in January 2008, specializes in large equipment and technology solutions [49]